Aerie Pharmaceuticals
AERI
AERI was delisted on the 18th of November, 2022.
159 hedge funds and large institutions have $1.47B invested in Aerie Pharmaceuticals in 2017 Q1 according to their latest regulatory filings, with 31 funds opening new positions, 38 increasing their positions, 69 reducing their positions, and 14 closing their positions.
121% more first-time investments, than exits
New positions opened: 31 | Existing positions closed: 14
91% more call options, than puts
Call options by funds: $16.7M | Put options by funds: $8.73M
15% more capital invested
Capital invested by funds: $1.28B → $1.47B (+$190M)
5% more funds holding
Funds holding: 151 → 159 (+8)
45% less repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 69
50% less funds holding in top 10
Funds holding in top 10: 6 → 3 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$116M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$18.4M |
| 3 |
SIG
Senator Investment Group
New York
|
+$17.8M |
| 4 |
Two Sigma Investments
New York
|
+$11.3M |
| 5 |
Invesco
Atlanta,
Georgia
|
+$11M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
-$46.5M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$30.7M |
| 3 |
Jennison Associates
New York
|
-$13.1M |
| 4 |
PI
Putnam Investments
Boston,
Massachusetts
|
-$9.38M |
| 5 |
ACA
Avoro Capital Advisors
New York
|
-$8.25M |
AERI Hedge Fund Activity: Q1 2017 in Review
159 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Aerie Pharmaceuticals (AERI) for Q1 2017, worth a combined $1.47B — up 15% from $1.28B a quarter earlier.
Buyers outnumbered sellers: 31 funds opened new AERI positions and 14 closed out — a net gain of 17 holders — while 38 added to existing stakes and 69 trimmed.
The largest buyer was BlackRock, adding an estimated $116M. The largest seller was Deerfield Management, cutting an estimated $46.5M.
- 159 institutional investors held Aerie Pharmaceuticals (AERI) as of Q1 2017, up from 151 in Q4 2016.
- Funds reported $1.47B of Aerie Pharmaceuticals stock for Q1 2017, up 15% quarter-over-quarter.
- 31 funds opened new Aerie Pharmaceuticals positions in Q1 2017 and 14 closed out, a net change of +17 holders.
- The largest Aerie Pharmaceuticals buyer in Q1 2017 was BlackRock, an estimated $116M added.
- The largest Aerie Pharmaceuticals seller in Q1 2017 was Deerfield Management, an estimated $46.5M sold.
Based on aggregated 13F filings for Q1 2017.